By Sabela Ojea
Immunovant said it received positive data from its ongoing 24-week Phase 2 clinical trial for its batoclimab treatment for Graves’ disease.
The clinical-stage immunology company on Wednesday said the trial results in patients with Graves’ disease meaningfully exceeded 50% response rates.
Batoclimab was generally well tolerated with no new safety signals observed in the initial data set.
Graves’ disease is an immune system disorder.
Write to Sabela Ojea at [email protected]
Read the full article here
